University of California-San Francisco, CA 94143-2922, USA.
Proc Am Thorac Soc. 2012 Jul;9(3):126-9. doi: 10.1513/pats.201112-052AW.
Acute lung injury is a common disorder with a high mortality rate, but previous efforts to develop drugs to treat this disorder have been unsuccessful. In an effort to develop more effective treatments, we have been studying the molecular pathways that regulate the dysfunction of alveolar epithelial cells and endothelial cells that serve as a final common pathway leading to alveolar flooding. Using integrin subunit knockout mice and antibodies we developed by immunizing these mice, we have found important and distinct roles for the αvβ6 integrin on epithelial cells and the αvβ5 integrin on endothelial cells in mediating increases in alveolar permeability in multiple models of acute lung injury. We have also found therapeutic effects of αvβ5 inhibition in two models of septic shock even when the antibody was administered to animals that were obviously ill. These results identify αvβ6 and αvβ5 as promising therapeutic targets for the treatment of acute lung injury and septic shock.
急性肺损伤是一种常见的疾病,死亡率很高,但以前开发治疗这种疾病的药物的努力都没有成功。为了开发更有效的治疗方法,我们一直在研究调节肺泡上皮细胞和内皮细胞功能障碍的分子途径,这些细胞是导致肺泡积水的最终共同途径。我们使用整合素亚基敲除小鼠和我们通过免疫这些小鼠开发的抗体,发现了αvβ6 整合素在上皮细胞和αvβ5 整合素在内皮细胞中在介导多种急性肺损伤模型中肺泡通透性增加方面的重要和独特作用。我们还发现了 αvβ5 抑制在两种感染性休克模型中的治疗效果,即使在将抗体施用于明显患病的动物时也是如此。这些结果表明,αvβ6 和 αvβ5 是治疗急性肺损伤和感染性休克的有前途的治疗靶点。